Case Report

Erythema necroticans: a rare reaction pattern in leprosy

K S Dhillon¹*, Deepak Sharma¹, Tarunveer Singh¹, Nishi Tandon², Gaurav Sarin¹, Areeba Khan¹, Soni Yadav¹, Sweksha Srivastava¹

¹Department of Dermatology, Era’s Lucknow Medical College, Lucknow, India
²Department of Pathology, Era’s Lucknow Medical College, Lucknow, India

Received: 06 February 2015
Accepted: 13 March 2015

*Correspondence:
Dr. K S Dhillon,
E-mail: kanwarjit29@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT
Leprosy reactions are rare expression of immunological perturbations that interrupt the usual chronic course and the clinical stability of patients with leprosy. They generally occur during antimycobacterial treatment and are characterized by the appearance of crops of brightly erythematous tender nodules or plaques. Erythema Necroticans (ENe) is an uncommon manifestation of Type 2 Erythema Nodosum Leprosum (ENL) reaction, encountered in lepromatous and borderline lepromatous cases of leprosy. Severe ENL can become vesicular or bullous and break-down and is termed Erythema Necroticans.

Keywords: Erythema Nodosum Leprosum, Erythema Necroticans, Lucio Phenomenon

INTRODUCTION
Leprosy is a major health problem in India with a prevalence of 3.22/10000, affecting all age groups from infancy to old age.¹ It is a disease of slow development that presents a wide spectrum of clinical, histopathological and immunological characterization. Leprosy reactions are rare and not well-known states that interrupt the usual chronic course and the clinical stability of patients with leprosy. They are expression of immunological perturbations.² Erythema Nodosum Leprosum (ENL) is an immune complex-mediated reaction that may complicate the course of multibacillary leprosy. It generally occurs during MDT and is characterized by the appearance of crops of brightly erythematous tender nodules or plaques. Severe ENL can become vesicular or bullous and break-down and is termed Erythema Necroticans.³ The extra-cutaneous manifestation include neuritis, iridocyclitis, orchitis and lymphadenopathy. Fever and other constitutional symptoms are usually associated with it.⁴

CASE REPORT
A 36 year old female patient came to our OPD with complaints of multiple painful raised lesions all over the body and fever on & off for last 8 months. She was asymptomatic 8 months back when she started developing intermittent fever, which was high grade in nature. It was associated with arthralgia and constitutional symptoms. Concurrent with febrile episodes, patient developed crops of multiple red, round elevated lesions all over the body (Figure 1, 2) with predilection for lower limbs (Figure 3). The lesions were very painful and usually occurred in the evening accompanied by fever. She did not have any other chronic ailment. Bowel and bladder habits were normal. On examination, patient was febrile. Pallor was present. Multiple, tender, erythematous, nodules were present all over the body including face interspersed with skin necrosis of various sizes lesions on forearm, gluteal region, thighs and legs. Local temperature was raised. Temperature sensation was lost over lesions of the extensor surface of the left forearm. Left ulnar nerve was thickened and tender.
Both lateral popliteal and radial nerves were also thickened. Diagnosis of leprosy was confirmed by slit-skin smear (ss): 5+ afb. Her HB was 7.8g/dl and her TLC was 19,000 cells/mm3 with neutrophilia. ESR and c-reactive protein were raised. All other biochemical & immunological parameters were within normal limits.

Histopathologic analysis showed poorly defined epithelioid granulomas with lepra cells and numerous inflammatory cells including neutrophils, lymphocytes and rare eosinophils centred around blood vessels, nerves and adnexal structure occupying the superficial, mid and deep dermis (Figure 4). MDT therapy was exhibited along with tab prednisone 30 mg twice a day initially with gradual tapering. Dose of cap clofazimine was increased to 100 mg thrice a day. Patient responded satisfactorily and ulcers started healing after institution of therapy.

**DISCUSSION**

Erythema Nodosum Leprosum (ENL) is an immune complex-mediated reaction that may complicate the course of multibacillary leprosy. It generally occurs during MDT and is characterized by the appearance of crops of brightly erythematous tender nodules or plaques. Severe ENL can become vesicular or bullous and break-down and is termed Erythema Necroticans. Erythema Nodosum Leprosum occurs usually during the treatment of lepromatous leprosy. However, there have been a fair number of reports of untreated lepromatous leprosy with subtle initial changes, presenting de novo as ENL, or it may present with extraordinary manifestations, often with long delay before the diagnosis of leprosy is considered. The probable trigger factors associated with ENL reaction include surgical operations, pregnancy, parturition, lactation, menstruation, trauma, inter-current illness, vaccination, physical or mental stress and sometime therapy. Tumor necrosis factor-α (TNF-α), a pro-inflammatory cytokine, plays an important role in the pathogenesis of ENL. There is activation of T-cell and macrophages, inducing production of large amounts of TNF-α. Additional source of TNF-α is the severe leukocytosis and the intense neutrophilic infiltrate in ENL lesions. Plasma levels of this cytokine have been found to be high during the episode of ENL. High CRP levels along with a positive correlation between elevated
TNF-α and CRP levels in the serum of ENL patients has been reported. Three types of ENL are identified: single acute ENL, multiple acute ENL (repeated discrete episodes) and chronic ENL (continuous episodes). 92% of ENL reactions are usually chronic and relapsing with unpredictable clinical course. Ulcers are an unusual presentation of leprosy. These occur as a result of loss of sensation (peripheral), ENL (rarely), or due to Lucio’s phenomenon. Besides the classic presentation of erythema nodosum, severe ENL very rarely presents as ulcerative skin lesions (erythema necroticans). Lucio phenomenon is a similar entity as Erythema necroticans but there is no fever or constitutional symptoms. Multiple drug therapy (MB-MDT) for borderline lepromatous leprosy should preferably be taken as per the recommendations of WHO. In addition, treatment with prednisolone should be instituted for 12 weeks course. The WHO has recommended the anti-inflammatory clofazimine for chronic and severe ENL and as steroid-sparing agent. However, it takes 4–6 weeks for the effect of clofazimine to be clinically detectable. Thus, it is not useful for the management of acute ENL. Thalidomide is now considered the drug of choice for ENL. It was approved by the FDA in 1998 in the acute treatment of moderate to severe ENL and preventing new episodes. The search for an effective alternatives, led to experiencing second-line drugs such as pentoxifyline, mycophenolate mofetil, azathioprine and infliximab with inconsistent results.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**